A Phase 2 interventional study of RO7965032 and Placebo in Geographic Atrophy Secondary to Age-Related Macular Degeneration, sponsored by Genentech, Inc.. Not yet recruiting. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Genentech, Inc. · Phase 2, Interventional, and Treatment
This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Genentech, Inc. is the lead sponsor of 507 studies on the registry; 23 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 50 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Ocular Inclusion Criteria for the Study Eye
Ocular Inclusion Criteria for Both Eyes
Exclusion Criteria:
General Exclusion Criteria - History of hypersensitivity, a severe allergic reaction or anaphylactic reaction to any component of the investigational drug injection
Ocular Exclusion Criteria for the Study Eye
Ocular Exclusion Criteria for the Non-Study Eye
- Non-functioning non-study eye defined as either BCVA of hand motion or worse or no physical presence of non-study eye (i.e., monocular)
Ocular Exclusion Criteria for Either Eye
Other protocol-defined inclusion/exclusion criteria may apply
Participants will receive RO7965032.
Drug: RO7965032
Participants will receive RO7965032.
Drug: RO7965032
Participants will receive placebo.
Drug: Placebo
RO7965032 will be administered as per the schedule defined in the protocol.
Placebo will be administered as per the schedule defined in the protocol.
Change of GA Lesion Area in the Study Eye
Time frame: Baseline up to approximately 48 weeks
Incidence and Severity of Ocular Adverse Events (AEs)
Time frame: Up to approximately 72 Weeks
Incidence and Severity of Non-Ocular AEs
Time frame: Up to approximately 72 Weeks
Change of GA Lesion Area in the Study Eye
Time frame: Baseline up to approximately 72 weeks
Change from Baseline in Best Correct Visual Acuity (BCVA) Score on the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart
Time frame: Baseline up to approximately 48 weeks
Change from Baseline in BCVA Score on the ETDRS Chart Under Low-luminance Conditions
Time frame: Baseline up to approximately 48 weeks
Incidence and Severity of Selected Findings in Ocular Examinations and Ocular Imaging
Time frame: Up to approximately 72 Weeks
Plasma Concentration of RO7965032
Time frame: Baseline up to approximately 72 weeks
Percent Change from Baseline in Levels of Target Protein in Plasma
Time frame: Baseline up to approximately 72 weeks
Percent Change from Baseline in Levels of Plasma Biomarker Activity
Time frame: Baseline up to approximately 72 weeks
Prevalence and Incidence of Anti-Drug Antibodies (ADAs)
Time frame: Baseline up to approximately 72 weeks
Recommended Dose of RO7965032
Time frame: Up to approximately 72 Weeks
No study locations are listed for this record.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genentech, Inc.